Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma.
about
Immunological Evasion in GlioblastomaImmunotherapy for cancer in the central nervous system: Current and future directionsOverview of current immunotherapeutic strategies for gliomaImmunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS SitesTherapeutic cancer vaccines: past, present, and futureReciprocal relationship between myeloid-derived suppressor cells and T cellsA role for G-CSF and GM-CSF in nonmyeloid cancersMyeloid-derived suppressor cells in cancer: therapeutic, predictive, and prognostic implicationsDendritic cell-based immunotherapy for glioma: multiple regimens and implications in clinical trialsDendritic Cell-Based Immunotherapy Treatment for Glioblastoma MultiformeArginine deprivation and immune suppression in a mouse model of Alzheimer's diseaseCoordinated regulation of myeloid cells by tumoursAssessing the role of STAT3 in DC differentiation and autologous DC immunotherapy in mouse models of GBMVaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4(+)IL17(+) response.Strategies for improving the reporting of human immunophenotypes by flow cytometry.Accumulation of myeloid-derived suppressor cells (MDSCs) induced by low levels of IL-6 correlates with poor prognosis in bladder cancerDurable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors.The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells.Identification of myeloid derived suppressor cells in the peripheral blood of tumor bearing dogs.Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemiaCirculating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma.Tumor-induced myeloid dysfunction and its implications for cancer immunotherapySubsets of airway myeloid-derived regulatory cells distinguish mild asthma from chronic obstructive pulmonary disease.Hypothesis: are neoplastic macrophages/microglia present in glioblastoma multiforme?Clinical benefit in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation.Myeloid derived suppressor cells are present at high frequency in neonates and suppress in vitro T cell responses.Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells.Identification of a 6-cytokine prognostic signature in patients with primary glioblastoma harboring M2 microglia/macrophage phenotype relevance.Critical Role of Mast Cells and Peroxisome Proliferator-Activated Receptor γ in the Induction of Myeloid-Derived Suppressor Cells by Marijuana Cannabidiol In Vivo.GBM Derived Gangliosides Induce T Cell Apoptosis through Activation of the Caspase Cascade Involving Both the Extrinsic and the Intrinsic Pathway.Cellular-based immunotherapies for patients with glioblastoma multiforme.Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma.Recent developments on immunotherapy for brain cancer.PI3K pathway inhibitors: potential prospects as adjuncts to vaccine immunotherapy for glioblastoma.Correlation between circulating myeloid-derived suppressor cells and Th17 cells in esophageal cancer.IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survivalExpression patterns of the immunomodulatory enzyme arginase 1 in blood, lymph nodes and tumor tissue of early-stage breast cancer patients.The intersection of cancer, cancer stem cells, and the immune system: therapeutic opportunities.Monomeric annexin A2 is an oxygen-regulated toll-like receptor 2 ligand and adjuvant.Yeast-Derived Particulate β-Glucan Treatment Subverts the Suppression of Myeloid-Derived Suppressor Cells (MDSC) by Inducing Polymorphonuclear MDSC Apoptosis and Monocytic MDSC Differentiation to APC in Cancer.
P2860
Q26746612-311D1947-E7F2-4AB3-B212-2F0F305653BEQ26750765-83F4178C-9683-43E0-AD8B-381FF18EC514Q26776345-810EB46E-611D-4DED-A35B-4E34B8E3B787Q26798402-97598E6B-1E43-4FCC-BD0A-6C7D0CB528EAQ26863283-9B7874F5-6E8E-4E1C-BD54-E1A754CBEAB0Q27000664-12BA4807-BBCC-4E1B-B88B-5F223097AC60Q27002515-8790D9C5-102A-48F9-AF5E-D9F848ADD064Q27014189-1CA73FEC-DC16-40BD-AA2F-37A0B2B713D2Q27014829-4AF4A7A2-74F6-4763-A978-EB16521DB23DQ28087485-75D8F2E5-946F-4B25-BA60-76F981171415Q28391826-25D2E629-1A22-45A2-ABE9-CAE5E9C4F6BCQ28395157-5199CF3F-6E2F-43DC-A772-DA3C89832AC2Q33578030-42708AED-1D6B-42EC-8330-E6C6D50815A9Q33606132-E5AC4FEF-3D1A-46D4-B1AA-60ACF5735997Q33822690-BAE26754-0946-45CA-8025-12E7812829CCQ33888808-8A2B3126-0EA3-4AE9-9B0C-90CD94114B9AQ34276759-154D3120-96DA-4D17-8B42-16B12A97F1CDQ34315871-665FDE39-373A-44BA-9923-C2CCBC3545CBQ34461732-0328A79D-CD6C-4726-881D-718416BFDE08Q34576982-362B2E6C-F4C6-4B15-B407-0F1372558DA5Q34600087-E5F21697-882A-43B8-9114-1BD6D3059B95Q34810257-BAAC965D-80AF-4545-AE66-821913D7F4BFQ35071370-D1728A04-5B7B-4D0E-93BD-B3B573DEE113Q35227405-930F3B39-91EC-44E5-98B6-183939326BC0Q35236790-0F1C0F3E-60D8-4E41-A9DD-1A2F7183B48FQ35271470-87B0DF06-E736-4BF1-9652-5979E46A27FBQ35553327-FADCC9E5-D567-44B1-91A6-8E5906835BB4Q35610772-2B1088A2-F8B6-4A61-9AD9-D483BFF80621Q35613040-62E3691D-CB17-43F0-A9B9-1500D41D5190Q35726496-4C54382D-8F47-41E7-A37A-A62A66768CD6Q35821404-740F70FA-301E-403F-8884-B69AEAC87A27Q35863183-36CD3F92-8F09-4374-9DF3-16737CFF34D8Q35992355-509EAB35-6CF3-4EAC-94B4-E10F8C256254Q36086507-384260AE-58DD-4F3C-9AD2-08CB0C2652B5Q36316728-A38BA8F7-4542-48D7-940F-3B98D220B0B6Q36405905-67D01512-2C93-4BF4-8DC2-0056FDD2FE74Q36456474-2769F85C-5273-44C2-BB8B-9B9FBDEF7C39Q36493820-DB2D508C-5C45-4495-A084-72AF7226A9C0Q36584178-1EA4861D-8ADA-44D5-8384-2CFDB8C2A3F3Q36600997-C2B6E358-5A37-4FEF-B594-3DF0FFAE2192
P2860
Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Myeloid-derived suppressor cel ...... newly diagnosed glioblastoma.
@en
type
label
Myeloid-derived suppressor cel ...... newly diagnosed glioblastoma.
@en
prefLabel
Myeloid-derived suppressor cel ...... newly diagnosed glioblastoma.
@en
P2093
P2860
P356
P1433
P1476
Myeloid-derived suppressor cel ...... newly diagnosed glioblastoma.
@en
P2093
Baisakhi Raychaudhuri
Brian Rini
Ernest C Borden
James Finke
Jennifer Ko
Joanna Ireland
Jorge Garcia
Michael A Vogelbaum
Patricia Rayman
P2860
P304
P356
10.1093/NEUONC/NOR042
P577
2011-06-01T00:00:00Z